Skip to main content
S&P 5007,563.87-0.21%DOW52,090.30+0.62%NASDAQ25,282.38-0.61%BTC$76,717.00-1.30%ETH$2,242.48-0.61%GOLD$3,961.20+1.60%OIL$96.55-7.27%
Smart Investors Daily
SID Premium
DR

NASDAQ · DRUG

Bright Minds Biosciences Inc.

Healthcare · Biotechnology

$54.98

Down-$29.26 (-53.22%)

Updated Nov 2, 2026, 7:44 PM

SID Score

3.4/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
630.71M
P/E ratio
-97.49
Dividend yield
0.00%
52-week range
$47.23 – $92.39
Volume
95.82K
Avg. volume
145.82K

Price performance · DRUG

DRUG price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

DRUG closed at $54.98 after 20 trading sessions, up 10.42% for the selected period.

Last close
$54.98
Period change
+10.42%
Period low
$48.25
Period high
$56.69
Daily close
View OHLC price history
DRUG OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$56.90$57.00$54.96$54.9895.82K
Oct 29, 2026$56.35$57.79$55.835$56.6967.54K
Oct 28, 2026$54.25$56.13$53.65$55.3271.1K
Oct 27, 2026$51.17$54.83$49.8875$54.0259.41K
Oct 26, 2026$52.72$53.46$50.29$51.0989.06K
Oct 23, 2026$51.77$52.65$51.00$52.4859.19K
Oct 22, 2026$50.44$53.105$49.92$52.69221.3K
Oct 21, 2026$55.34$59.71$49.80$50.44156.37K
Oct 20, 2026$54.00$57.495$54.00$55.2094.7K
Oct 19, 2026$53.07$54.27$49.87$53.82156.32K
Oct 16, 2026$54.15$54.15$51.30$51.3056.03K
Oct 15, 2026$51.80$55.75$51.245$54.21121.46K
Oct 14, 2026$50.52$52.96$49.06$50.71199.36K
Oct 13, 2026$54.01$54.35$50.99$51.36246.57K
Oct 12, 2026$53.89$55.20$53.27$54.01134.58K
Oct 9, 2026$52.45$55.78$51.91$54.0598.41K
Oct 8, 2026$51.01$52.64$49.29$52.0067.93K
Oct 7, 2026$47.23$53.01$47.23$52.00688.82K
Oct 6, 2026$49.79$50.00$47.60$48.25107.66K
Oct 5, 2026$50.69$51.335$49.085$49.7955.95K

Latest DRUG news

The latest Smart Investors Daily articles mentioning DRUG.

Stock researchCompany · Overview

DRUG research

Overview

Company profile and research snapshot.

Company profile

Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$82.50
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 8, 2026

Bright Minds Biosciences And 2 More Canadian Biotech Stocks

Oil prices are climbing again as shipping attacks in the Gulf raise fresh worries about inflation and higher interest rates that can pressure many sectors. Canadian biotech stocks sit slightly off to the side of this drama, with product pipelines tied more to medical science than to energy cycles. That disconnect can appeal right now. This article highlights three Canadian biotech ideas identified by our quality focused screener. The three Canadian biotech stocks below are just a starting...

Yahoo · Sep 30, 2026

Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the P

Yahoo · Sep 30, 2026

Auxly Cannabis Group And 2 Other Canadian Biotech Stocks To Watch

Bond yields have surged to levels last seen before the global financial crisis, which makes future cash flows harder to value and puts every growth story under a harsher spotlight. That pressure has not spared Canadian biotech shares, yet it also filters out weaker balance sheets and stretched valuations. This article highlights 3 Canadian biotechnology stocks from our quality focused screener that could merit a closer look today. The three stocks below are a small sample of what screens well...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By